Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Britain Courts Anthropic Amid US Defense Department Dispute 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
SAN DIEGO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Evofem, a biotechnology company focused on the development and commercialization of women's health products, announced today that it met with representatives of the U.S. Food and Drug Administration ("FDA") in a Pre-IND (Investigational New Drug) meeting for its lead product, Amphora to be evaluated for the prevention of recurrence of Bacterial Vaginosis (BV). Research suggests Amphora, a vaginally delivered topical gel, works through a novel mechanism of action against several bacterial and viral organisms. As a result of this meeting, Evofem will be developing a formal research protocol to begin clinical studies.
Saundra Pelletier, Chief Executive Officer of Evofem, said, "I am pleased with the guidance we received and the clarification of the work necessary to file an Investigational New Drug Application. This area of development is consistent with our platform of finding and developing promising healthcare solutions that address unmet needs for women worldwide."
A New Drug Application for Amphora as a non-hormonal, vaginal gel contraceptive was accepted by the United States Food and Drug Administration (FDA) in July of 2015.
About Evofem
Evofem Holdings, Inc. seeks to address a growing global contraceptive market, while delivering effective, woman-controlled products with global distribution. Evofem Holdings, Inc. has two lead product candidates: Amphora, a non-hormonal contraceptive gel, and the Nestorone Ring, a one-year contraceptive vaginal ring, both of which have completed Phase III clinical studies.
For further information on the Company, please visit: www.evofem.com
About Amphora
Amphora is a non-hormonal vaginal gel. In addition to the regulatory filing for approval as a contraceptive, Amphora is being investigated for microbicidal properties to develop a potential multipurpose prevention technology. Amphora works by restoring the vaginal pH levels to those consistent with a healthy vaginal environment.
CONTACT: Media Inquiries
Nicole Beckstrand
[email protected]
858.550.1900 ext. 250
